生物试剂
>
生化试剂
>
信号通路
> Bay 60-7550
加入收藏 取消收藏

Bay 60-7550  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg 10mg 100mg in glass bottle
溶解性：溶于DMSO(2mg/mL)
产品描述：基本信息 产品编号： B11405 产品名称： Bay 60-7550 CAS: 439083-90-6   储存条件 粉末 -20℃ 四年     分子式： C27H32N4O4 溶于液体 -80℃ 六个月 分子量 476.57 -20℃ 一个月 化学名：  2-(3,4-Dimethoxybenzyl)-7-{(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl}-5-methyllimidazo[5,1-f][1,2,4]triazin-4(3H)-one Solubility (25°C)：   体外:   DMSO ≥33.3mg/mL(69.87mM) Ethanol   Water   体内(现配现用): 1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline，Solubility:≥2.5mg/mL(5.25mM);Clear solution 此⽅案可获得≥2.5mg/mL(5.25mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到400μL PEG300中，混合均匀；向上述体系中加⼊50μL Tween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。 2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility:≥2.5mg/mL(5.25mM);Clear solution 此⽅案可获得≥2.5mg/mL(5.25mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。 3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:≥2.5mg/mL(5.25mM);Clear solution 此⽅案可获得≥2.5mg/mL(5.25mM，饱和度未知)的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL⽟⽶油中，混合均匀。 ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.0983mL 10.4916mL 20.9833mL 5mM 0.4197mL 2.0983mL 4.1967mL 10mM 0.2098mL 1.0492mL 2.0983mL   生物活性 产品描述 一种有效，选择性的 PDE2 抑制剂。 靶点 Ki: 3.8±0.2nM (PDE2) 体外研究 Bay 60-7550 (1μM) increases cGMP in the neuronal cultures compared with control [F(6,14)=12.97, p<0.05 for Bay 60-7550]. Bay 60-7550 in the presence of NMDA (30μM) results in further increases in cGMP compared with NMDA alone. The NMDA receptor antagonist MK-801 (10μM) blocks both Bay 60-7550+NMDA-induced elevation in cGMP in neuronal cultures Compared with untreated control cells, proliferation of PASMCs from IPAH patients is significantly reduced by BAY 60-7550 (1μM) 体内研究 The PDE2 inhibitors Bay 60-7550 (1mg/kg) reverses restraint stress-induced alterations in behavior, resulting in increased percentages of open-arm entries and open-arm time compared with the vehicle + restraint stress condition. In nonstressed mice, Bay 60-7550 produces a dose-dependent increase in percentages of open-arm entries and open-arm time compared with the vehicle-treated group; significant increases are observed at a dose of 3mg/kg. In nonstressed mice, Bay 60-7550 increases, in a dose-dependent manner, the number of head-dips and time spent head-dipping, compared with vehicletreated mice; significant increases are observed at doses of 1 and 3mg/kg   推荐实验方法(仅供参考) Kinase Assay COS-7 cells are maintained in complete DMEM (containing 10% fetal calf serum, 100 units/mL penicillin G, 100mg/mL streptomycin, and 400μM L-alanyl-L-glutamine) at 37°C in 5% CO2 atmosphere. A PDE2 expression plasmid is introduced into COS-7 cells using the FuGENE6 transfection reagent. Cells are lysed in solubilization buffer (275 mM NaCl, 1.5 mMmgCl2, 2 mM EGTA, 2% Triton X, 20% glycerol, and 40 mM Tris-HCl), and the cell lysates are used in the immunoprecipitation procedures. A protein A-agarose bead slurry (100 μL) is washed three times with ice-cold phosphate-buffered saline (100 mM NaCl, 2.7 mM KCl, 10.6 mM Na2HPO4, and 1.6 mM NaH2PO4) and mixed with the 5 μg of PDE2 antibody and 100 μL (2 μg/μL) of the lysate sample and rotated overnight at 4°C. The bead/sample mixture is then centrifuged at 1000g to separate the beads from the supernatant. The beads are resuspended in 100 μL of ice-cold lysis buffer (20 mM Tris, pH 7.4, 140 mM NaCl, 0.75 mMmgCl2, 1 mM EGTA, 1% Triton X-100, and 20% glycerol, containing protease and phosphatase inhibitors) to elute the PDE2 for use in the enzyme activity assays. The PDE2 activity assay is done. The recombinant PDE2 enzyme derived from COS-7 cell expression and diluted in KHEM buffer (50 mM KCl, 50 mM HEPES, 10 mM EGTA, and 1.9 mMmgCl2, pH 7.2) is mixed with different concentrations of PDE2 inhibitors (Bay 60-7550, ND7001, and EHNA) and [3H]cGMP/cGMP (5μM) as the substrate. The mixture is then incubated for 30 min at 37°C (100 μL of reaction volume). To convert the [3H]GMP to [3 H]guanosine, samples are incubated with snake venom from Crotalus atrox for 30 min at 37°C. The samples are then vortexed with a freshly prepared slurry of Dowex/water/ethanol [1:1:1, v/v] and then centrifuged for 10 min. [3H]Guanosine in the supernatant is then quantified by liquid scintillation counting. Bay 60-7550 is dissolved in dimethyl sulfoxide, EHNA is dissolved in distilled water, and ND7001 is dissolved in ethanol as 10 mM stocks and then diluted for use in assays with 20 mM Tris, pH 7.4; final concentrations of the respective solvents did not affect the assay. IC50 values at a single substrate concentration are determined by nonlinear regression analysis of the log concentration-response curves for each PDE2 inhibitor; Ki values are calculated Cell Assay Growth of human distal pulmonary artery smooth muscle cells isolated from patients with idiopathic pulmonary arterial hypertension (IPAH) or control cells from adults undergoing transplant or lung resection for suspected malignancy, are monitored following treatment with BAY 60-7550 (1μM), ANP (1μM), DETA-NONOate (10μM), or Treprostinil (1μM), alone or in combination Animal Administration Mice Male ICR mice weighing 28 to 35 g are used. Bay 60-7550 (0.5, 1, and 3mg/kg), ND7001 (0.5, 1.0, and 3mg/kg), Detanonoate (0.5mg/kg), L-NAME (50mg/kg), or Diazepam (1mg/kg) is administered after restraint stress and 30 min before behavioral testing. Mice also are treated with Bay 60-7550 (3mg/kg), ND7001 (3mg/kg), Detanonoate, (0.5mg/kg), L-NAME (50mg/kg), or diazepam (1mg/kg) in the absence of restraint stress; drugs are administered 30 min before the behavioral tests. Bay 60- 7550 shows 50-fold selectivity for PDE2 compared with PDE1, 100-fold compared with PDE5, and greater than 200-fold compared with the other PDE families. ND7001 exhibits at 1east 100-fold selectivity for inhibition of PDE2 relative to other PDE families. For antagonism tests to assess the role of cGMP signaling in the behavioral effects of the PDE2 inhibitors, ODQ, an inhibitor of soluble guanylyl cyclase (20mg/kg), is administered 20 min before Bay 60-7550 or ND7001.
保存条件：-20℃

猜你喜欢